**Name of Journal:** *World Journal of Gastrointestinal Surgery*

**Manuscript NO:** 60730

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Functional transition: Inconsistently parallel to the increase in future liver remnant volume after preoperative portal vein embolization**

Tsuruga Y *et al*. Functional transition after PVE

Yosuke Tsuruga, Toshiya Kamiyama, Hirofumi Kamachi, Tatsuya Orimo, Shingo Shimada, Akihisa Nagatsu, Yoh Asahi, Yuzuru Sakamoto, Tatsuhiko Kakisaka, Akinobu Taketomi

**Yosuke Tsuruga, Toshiya Kamiyama, Hirofumi Kamachi, Tatsuya Orimo, Shingo Shimada, Akihisa Nagatsu, Yoh Asahi, Yuzuru Sakamoto, Tatsuhiko Kakisaka, Akinobu Taketomi,** Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan

**Author contributions:** Tsuruga Y, Kamiyama T and Kamiachi H designed the research study; Tsuruga Y, Kakisaka T, Orimo T, Shimada S, Nagatsu A, Asahi Y and Sakamoto Y gave substantial contributions to acquisition of data; Tsuruga Y and Kamiyama T analyzed the data and wrote the manuscript; Taketomi A gave final approval of the version to be published; all authors have read and approved the final manuscript.

**Corresponding author: Yosuke Tsuruga, MD, PhD, Doctor,** Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, North 15, West 7, Kita-ku, Sapporo 060-8638, Japan. ytsuruga@d2.dion.ne.jp

**Received:** November 16, 2020

**Revised:** December 26, 2020

**Accepted:** January 14, 2021

**Published online:**

**Abstract**

BACKGROUND

Preoperative portal vein embolization (PVE) is a widely used strategy to enable major hepatectomy in patients with insufficient liver remnant. PVE induces hypertrophy of the future liver remnant (FLR) and a shift of the functional reserve to the FLR. However, whether the increase of the FLR volume (FLRV) corresponds to the functional transition after PVE remains unclear.

AIM

To investigate the sequential relationship between the increase in FLRV and functional transition after preoperative PVE using 3-dimensional (3D) computed tomography (CT) and 99mTc-galactosyl-human serum albumin (99mTc-GSA) single-photon emission computed tomography (SPECT) fusion images.

METHODS

Thirty-three patients who underwent major hepatectomy following PVE at the Department of Gastroenterological Surgery I, Hokkaido University Hospital between October 2013 and March 2018 were enrolled. Three-phase dynamic multidetector CT and 99mTc-GSA SPECT scintigraphy were performed at pre-PVE, and at 1 and 2 wk after PVE; 3D 99mTc-GSA SPECT CT-fused images were constructed from the Digital Imaging and Communications in Medicine data using 3D image analysis system. Functional FLRV (FFLRV) was defined as the total liver volume × (FLR volume counts/total liver volume counts) on the 3D 99mTc-GSA SPECT CT-fused images. The calculated FFLRV was compared with FLRV.

RESULTS

FFLRV increased by a significantly larger extent than FLRV at 1 and 2 wk after PVE (*P* < 0.01). The increase in FFLRV and FLRV was 55.1% ± 41.6% and 26.7% ± 17.8% (*P* < 0.001), respectively, at 1 wk after PVE, and 64.2% ± 33.3% and 36.8% ± 18.9% (*P* < 0.001), respectively, at 2 wk after PVE. In 3 of the 33 patients, FFLRV levels decreased below FLRV at 2 wk. One of the three patients showed rapidly progressive fatty changes in FLR. The biopsy at 4 wk after PVE showed macro- and micro-vesicular steatosis of more than 40%, which improved to 10%. Radical resection was performed at 13 wk after PVE. The patient recovered uneventfully without any symptoms of postoperative liver failure.

CONCLUSION

The functional transition lagged behind the increase in FLRV after PVE in some cases. Evaluating both volume and function is needed to determine the optimal timing of hepatectomy after PVE.

**Key Words:** Preoperative portal vein embolization; Hepatectomy; 99mTc-galactosyl-human serum albumin single-photon emission computed tomography; Future liver remnant volume; Functional transition; Fatty liver change

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Tsuruga Y, Kamiyama T, Kamachi H, Orimo T, Shimada S, Nagatsu A, Asahi Y, Sakamoto Y, Kakisaka T, Taketomi A. Functional transition: Inconsistently parallel to the increase in future liver remnant volume after preoperative portal vein embolization. *World J Gastrointest Surg* 2021; 13(2): 153-163

URL: https://www.wjgnet.com/1948-9366/full/v13/i2/153.htm

DOI: https://dx.doi.org/10.4240/wjgs.v13.i2.153

**Core Tip:** Preoperative portal vein embolization (PVE) induces hypertrophy of the future liver remnant (FLR) and a shift of the functional reserve to the FLR. However, whether the increase in FLR volume (FLRV) corresponds to the functional transition after PVE remains unclear. We investigated the sequential relationship between the increase in the FLRV and the functional transition after preoperative PVE. The functional transition lagged behind the increase in FLRV after PVE in 3 of the 33 cases. Evaluating both volume and function is needed to determine the optimal timing of hepatectomy after PVE.

**INTRODUCTION**

Liver resection is often the only option for long-term survival of patients with primary or secondary liver cancer. The mortality rate after major liver resection has been reported to be 2.0%-6.8%, which is mainly due to postoperative liver failure[1-3]. Small future liver remnant volume (FLRV) is a predictor of perioperative morbidity and mortality[4]. For patients with a normal liver, a remnant volume of more than 20%-40% of the total liver or standardized liver volumes has been proposed as the threshold of surgical safety[5-9].

Preoperative portal vein embolization (PVE) is widely used to enable major liver resection with insufficient liver remnant[10-13]. PVE induces hypertrophy of the future liver remnant (FLR) and a shift of the functional reserve to FLR[14,15]. However, whether the increase of the FLRV corresponds to the functional transition after PVE remains unclear.

99mTc-galactosyl-human serum albumin (99mTc-GSA) was developed as a liver scintigraphy agent that binds to the asialoglycoprotein receptor on hepatocytes[16]. 99mTc-GSA scintigraphy is frequently used for evaluating the hepatic functional reserve. 99mTc-GSA single-photon emission computed tomography (SPECT) can determine the regional distribution of hepatic function[17]. However, the spatial resolution of 99mTc-GSA SPECT is low. Furthermore, it is difficult to precisely estimate the functional reserve of FLR in patients requiring complex resection. Recently, computed tomography (CT)/99mTc-GSA SPECT fusion imaging has been reported to enable the precise evaluation of hepatic function distribution owing to the high spatial resolution provided by CT[14]. We previously reported the usefulness of calculating the functional hepatic resection rate using 3-dimensional (3D) CT/99mTc-GSA SPECT fusion imaging for patients undergoing major hepatectomy by correlation with the parenchymal hepatic resection rate (PHRR)[18]. Precise measurement of the changes in both volume and function is presumed to be obtained simultaneously using 3D CT/99mTc-GSA SPECT fusion imaging.

In the present study, we investigated the sequential relationship between the increase in FLRV and the functional transition after preoperative PVE using 3D CT/99mTc-GSA SPECT fusion imaging to develop a strategy for preventing fatal liver failure after major hepatectomy.

**MATERIALS AND METHODS**

We retrospectively analyzed the data of 33 patients who underwent major hepatectomy following PVE at the Department of Gastroenterological Surgery I, Hokkaido University Hospital between October 2013 and March 2018. This study was reviewed and approved by the Institutional Review Board of Hokkaido University Hospital for Clinical Research (approval number: 018-0263), which waived the need for written informed consent due to the retrospective design of the study. The baseline characteristics of the patients are shown in Table 1. At our institution, preoperative PVE is generally performed for patients with a PHRR of > 60%[19]. All patients underwent a three-phase dynamic multidetector CT scan and 99mTc-GSA scintigraphy at pre-PVE, and at 1 and 2 wk after PVE.

***Preoperative PVE***

The ipsilateral approach was routinely used, with the contralateral approach reserved for patients for whom the ipsilateral approach was judged to be unsuitable. Ethanol is used as the embolizing agent at our institution[20]. The intrahepatic portal vein was punctured under sonographic guidance. A guidewire was inserted into the portal vein through the needle, followed by the introduction of a 5.5-French sheath introducer. Balloon occlusion was performed, and contrast material was injected until the targeted portal branches were enhanced. The balloon was then deflated, and an equal amount (equivalent to the previously injected contrast material) of 0.5% lidocaine was injected. Finally, balloon occlusion was repeated, and an equal amount of ethanol (equivalent to the previously injected contrast material or 0.5% lidocaine) was injected. The balloon was deflated after 5 min, and the complete embolization of targeted vessels was determined by test portography through a manual injection of contrast medium. Subsequently, for incomplete embolization, the ethanol injections were repeated in the same way. Finally, the 5.5-French sheath was extracted by packing the puncture tract with gelatin sponge torpedoes.

***Hepatectomy***

An algorithm (Hokkaido University Algorithm) incorporating the indocyanine green retention at 15 min and FLRV is generally used to determine the nature of sectionectomy required, *e.g.*, bisectionectomy[19]. The timing of the operation after PVE was generally determined by a PHRR decrease of less than 60% at least two weeks after PVE.

***3D CT/99mTc-GSA SPECT fusion imaging***

Three-phase dynamic CT scan was performed with a 320-row multidetector device (Aquilion ONE; Toshiba Medical Systems Co., Otawara, Japan). The obtained Digital Imaging and Communications in Medicine (DICOM) data were imported to the 3D image analysis system (Volume Analyzer SYNAPSE VINCENT; Fuji Film Medical, Tokyo, Japan)[21]. Three-dimensional images were reconstructed from the DICOM data.

99mTc-GSA scintigraphy was performed separately from CT. Dynamic scanning was initially performed using a large-field view gamma camera (E.CAM; Siemens, Tokyo, Japan) in an anterior view, equipped with a low-energy high-resolution collimator, with the patient in a supine position after a bolus intravenous injection of 185 MBq of 99mTc-GSA. Dynamic planar images were obtained for 30 min by 147 serial frames (60 × 1 s, 87 × 20 s), with a matrix size of 128 × 128. Hepatic SPECT images were acquired after the dynamic study. The DICOM data obtained from SPECT were also imported to the SYNAPSE VINCENT and subsequently fused with the 3D CT images. Functional FLRV (FFLRV) was calculated using the following formula: FFLRV (mL) = [(total liver volume counts - resection volume counts)/total liver volume counts) × total liver volume] (mL).

***Calculation of FLR to spleen attenuation ratio***

Hounsfield unit attenuation values of the FLR and spleen at 10 regions of interest were obtained using unenhanced CT, and the average values were calculated. The regions were selected while taking care to avoid the vessels. The ratio of liver to spleen attenuation was then calculated.

***Statistical analysis***

The statistical analyses were performed using EZR software, version 1.36 (Saitama Medical Center, Jichi Medical University, Saitama, Japan)[22]. The Wilcoxon signed rank test was used for comparing FFLRV and FLRV.

**RESULTS**

***Change in FFLRV and FLRV after PVE***

FFLRV increased by a significantly larger extent than FLRV at 1 and 2 wk after PVE (Figure 1A). The FFLRV and FLRV were 55.1% ± 41.6% and 26.7% ± 17.8% (*P* < 0.001), respectively, at 1 wk after PVE, and 64.2% ± 33.3% and 36.8% ± 18.9% (*P* < 0.001), respectively, at 2 wk after PVE. We also compared FLRV and FFLRV between the groups with and without preoperative biliary drainage. However, no significant differences were observed between these two groups (Table 2). The similar tendency of the sequential increase in FLRV and FFLRV after PVE was observed in these two groups (Figure 1B and C).

***Change in the difference between FLRV and FFLRV***

We calculated the difference by subtracting the FLRV values from FFLRV values of all patients before and after PVE (Figure 2). The results after PVE were almost entirely positive, while in 3 patients, the FFLRV became lower than the FLRV at 2 wk after PVE. FFLRV caught up with FLRV at 3 wk after PVE in 2 of these 3 patients. Subsequently, all the patients were classified into two groups: FLRV superior group included those in whom FFLRV decreased below the FLRV at 2 wk after PVE and the FFLRV superior group included the remaining patients. No significant differences were observed when the background factors were compared between these two groups (Table 3).

***Representative case***

A 77-year-old woman was diagnosed with hilar cholangiocarcinoma.Right hepatectomy and caudal lobectomy were planned. PVE was performed because the initial resection ratio was 71.3%. FLRV increased from 414 mL to 796 mL at two weeks after PVE; however, the change in function lagged behind the increase in FLRV for 3 wk (Figure 3A). The decrease in the FLR to spleen CT attenuation ratio at up to 5 wk after PVE indicated fatty changes in the FLR. Biopsy at 4 wk after PVE showed macro- and micro-vesicular steatosis of more than 40% (Figure 3B). FLRV on CT was sufficient to proceed with resection, although we postponed the operation until the FLR to spleen CT attenuation ratio recovered. Pioglitazone was administered for the treatment of nonalcoholic fatty liver disease. The CT attenuation ratio recovered at 7 wk after PVE, and radical liver resection was successfully performed at 13 wk. Intraoperative biopsy showed that the steatosis had improved to approximately 10% (Figure 3C). The patient recovered uneventfully without any symptoms of postoperative liver failure.

**DISCUSSION**

In the present study investigating the sequential relationship between the increase in FLRV and the functional changes after preoperative PVE, we found that in almost all cases, the increase in FLRV lagged behind that of the FFLRV. However, several cases of marked lagging of the FFLRV behind the increase in FLRV within the first 2 wk were observed.

Embolized lobe atrophy and FLR hypertrophy occur after PVE[12]. A meta-analysis reported the mean relative rate of hypertrophy of FLR to be 43.1%[23]. In this study, the increase in FLRV at 2 wk was 36.8% ± 18.9%, which is roughly in accordance with the previously published mean value. The increase in FFLRV at 2 wk (64.2% ± 33.3%) was greater than that of the FLRV. Beppu *et al*[14] also reported the marked increase in FLR after PVE using 99mTc-GSA scintigraphy SPECT-CT fusion data. They reported that the percentage increase in FLRV after PVE was greater than that of the non-tumorous remnant liver volume. Moreover, the increased portal flow, heat shock protein (HSP), ATP (adenosine triphosphate) concentrations, and DNA synthesis in the non-embolized liver after PVEmay be related to the mechanism of hyper-function of the FLR[24]. Functional transition evidently occurs after PVE because of the hypofunction of the embolized lobe and hyperfunction of the FLR.

Moreover, as for the sequential relationship between FLRV increases and FFLRV, 3 patients experienced a marked decrease in FFLRV to levels below the FLRV at 2 wk after PVE. While these patients did not share obvious similarities, rapidly progressive fatty changes in FLR were observed after PVE in 1 patient. Tsai *et al*[25] reported the first case of acute non-alcoholic fatty change in the liver after PVE, suggesting a relationship between hemodynamic changes after PVE and fatty changes. A time-dependent fatty change in FLR was proven by biopsy in our study. There is a possible hypothesis on the mechanism underlying these fatty changes. Miyake *et al*[26] reported that HSP70 Levels after right PVE were 2- to 4-fold higher in the non-embolized lobe than in the embolized lobe in 4 of 5 patients[24,26]. The patient who did not experience this marked increase ultimately died of hepatic failure after extended right hepatic lobectomy. Archer *et al*[27] also showed that the decrease in HSP72 by siHSP72 Leads to lipid accumulation in the primary mouse hepatocytes. Thus, inhibition of HSP70 induction in the FLR after PVE may lead to fatty changes in the FLR and delay functional transition.

In contrast, it was demonstrated that liver steatosis quantified with gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid -enhanced liver MRI was associated with an impaired growth of FLR after portal vein occlusion in clinical cases[28], and steatotic rats fed with a methionine-choline-deficient diet demonstrated impaired liver generation and less FLR function compared to control rats after portal vein ligation[29].

Increase in FLRV has generally only been used to determine the timing of hepatectomy after PVE; however, the risk of postoperative liver failure remains in some cases due to the functional transition lagging behind the increase in FLRV after PVE. However, in most cases, the increase in FFLRV is larger than that of FLRV after PVE. Therefore, both FLRV and FFLRV must be carefully considered when hepatectomy is performed. Furthermore, besides CT volumetry, evaluation of function with GSA is required.

Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) enables rapid and extensive hypertrophy of the remnant liver[30]. However, higher morbidity and mortality rates have been reported compared to the conventional methods of volume enhancement[31]. Olthof *et al*[32] reported that the increase in the function of the FLR was less than that of the volume after stage 1. Calculation of FFLRV using 3D CT and 99mTc-GSA SPECT fusion images may contribute to the improvement of the safety of ALPPS.

One of the limitations of this study is that only one of three patients who experienced a marked decrease in FFLRV to levels below the FLRV showed fatty changes in FLR after PVE. There could be multiple causes underlying the lagging of FFLRV behind the increase of FLRV. A large prospective study is needed to elucidate the underlying mechanism of the functional transition delay and fatty changes in FLR. Additionally, the effect of functional transition delay in clinical results, including postoperative liver failure, should be investigated in future studies.

**CONCLUSION**

Although in most cases, the increase in FLRV lagged behind that of the FFLRV after PVE, the functional transition lagged behind the increase in FLRV in some cases. Evaluation of both volume and function by CT volumetry and 99mTc-GSA is required to determine the optimal timing of hepatectomy after PVE.

**ARTICLE HIGHLIGHTS**

***Research background***

Preoperative portal vein embolization (PVE) is a widely used strategy to enable major hepatectomy in patients with insufficient liver remnant. The timing of hepatectomy after PVE has been usually determined from future liver remnant volume (FLRV) based on computed tomography (CT) volumetry.

***Research motivation***

PVE induces hypertrophy of the future liver remnant (FLR) and a shift of the functional reserve to the FLR. However, whether the increase in FLRV corresponds to the functional transition after PVE remains uncertain.

***Research objectives***

The present study investigated the sequential relationship between the increase in the FLRV and functional transition after preoperative PVE.

***Research methods***

Thirty-three patients who underwent major hepatectomy following PVE were enrolled in this retrospective study. Functional FLRV (FFLRV) was defined as the total liver volume × (FLR volume counts / total liver volume counts) on the 3-dimensional 99mTc-galactosyl-human serum albumin (99mTc-GSA) single-photon emission CT CT-fused images. The calculated FFLRV was compared with FLRV.

***Research results***

FFLRV increased by a significantly larger extent than FLRV at 1 and 2 wk after PVE (*P* < 0.01); however, in 3 of the 33 patients, FFLRV levels decreased below FLRV at 2 wk. One of the three patients showed rapidly progressive fatty changes in FLR.

***Research conclusions***

The results indicate that functional transition lagged behind the increase in FLRV after PVE in some cases. The evaluation of both volume and function by CT volumetry and 99mTc-GSA are needed to determine the optimal timing of hepatectomy after PVE for preventing fatal liver failure after major hepatectomy.

***Research perspectives***

Further research is needed to elucidate the underlying mechanism of the functional transition delay and fatty changes in FLR.

**REFERENCES**

1 **Reissfelder C**, Rahbari NN, Koch M, Kofler B, Sutedja N, Elbers H, Büchler MW, Weitz J. Postoperative course and clinical significance of biochemical blood tests following hepatic resection. *Br J Surg* 2011; **98**: 836-844 [PMID: 21456090 DOI: 10.1002/bjs.7459]

2 **Belghiti J**, Hiramatsu K, Benoist S, Massault P, Sauvanet A, Farges O. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. *J Am Coll Surg* 2000; **191**: 38-46 [PMID: 10898182 DOI: 10.1016/S1072-7515(00)00261-1]

3 **Mullen JT**, Ribero D, Reddy SK, Donadon M, Zorzi D, Gautam S, Abdalla EK, Curley SA, Capussotti L, Clary BM, Vauthey JN. Hepatic insufficiency and mortality in 1,059 noncirrhotic patients undergoing major hepatectomy. *J Am Coll Surg* 2007; **204**: 854-62; discussion 862-4 [PMID: 17481498 DOI: 10.1016/j.jamcollsurg.2006.12.032]

4 **Jarnagin WR**, Gonen M, Fong Y, DeMatteo RP, Ben-Porat L, Little S, Corvera C, Weber S, Blumgart LH. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. *Ann Surg* 2002; **236**: 397-406; discussion 406-407 [PMID: 12368667 DOI: 10.1097/00000658-200210000-00001]

5 **Kishi Y**, Abdalla EK, Chun YS, Zorzi D, Madoff DC, Wallace MJ, Curley SA, Vauthey JN. Three hundred and one consecutive extended right hepatectomies: evaluation of outcome based on systematic liver volumetry. *Ann Surg* 2009; **250**: 540-548 [PMID: 19730239 DOI: 10.1097/SLA.0b013e3181b674df]

6 **Shoup M**, Gonen M, D'Angelica M, Jarnagin WR, DeMatteo RP, Schwartz LH, Tuorto S, Blumgart LH, Fong Y. Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. *J Gastrointest Surg* 2003; **7**: 325-330 [PMID: 12654556 DOI: 10.1016/S1091-255X(02)00370-0]

7 **Vauthey JN**, Chaoui A, Do KA, Bilimoria MM, Fenstermacher MJ, Charnsangavej C, Hicks M, Alsfasser G, Lauwers G, Hawkins IF, Caridi J. Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations. *Surgery* 2000; **127**: 512-519 [PMID: 10819059 DOI: 10.1067/msy.2000.105294]

8 **Kubota K**, Makuuchi M, Kusaka K, Kobayashi T, Miki K, Hasegawa K, Harihara Y, Takayama T. Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors. *Hepatology* 1997; **26**: 1176-1181 [PMID: 9362359 DOI: 10.1053/jhep.1997.v26.pm0009362359]

9 **Schindl MJ**, Redhead DN, Fearon KC, Garden OJ, Wigmore SJ; Edinburgh Liver Surgery and Transplantation Experimental Research Group (eLISTER). The value of residual liver volume as a predictor of hepatic dysfunction and infection after major liver resection. *Gut* 2005; **54**: 289-296 [PMID: 15647196 DOI: 10.1136/gut.2004.046524]

10 **Kinoshita H**, Sakai K, Hirohashi K, Igawa S, Yamasaki O, Kubo S. Preoperative portal vein embolization for hepatocellular carcinoma. *World J Surg* 1986; **10**: 803-808 [PMID: 3022488 DOI: 10.1007/BF01655244]

11 **Giraudo G**, Greget M, Oussoultzoglou E, Rosso E, Bachellier P, Jaeck D. Preoperative contralateral portal vein embolization before major hepatic resection is a safe and efficient procedure: a large single institution experience. *Surgery* 2008; **143**: 476-482 [PMID: 18374044 DOI: 10.1016/j.surg.2007.12.006]

12 **Nagino M**, Kamiya J, Nishio H, Ebata T, Arai T, Nimura Y. Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer: surgical outcome and long-term follow-up. *Ann Surg* 2006; **243**: 364-372 [PMID: 16495702 DOI: 10.1097/01.sla.0000201482.11876.14]

13 **Abulkhir A**, Limongelli P, Healey AJ, Damrah O, Tait P, Jackson J, Habib N, Jiao LR. Preoperative portal vein embolization for major liver resection: a meta-analysis. *Ann Surg* 2008; **247**: 49-57 [PMID: 18156923 DOI: 10.1097/SLA.0b013e31815f6e5b]

14 **Beppu T**, Hayashi H, Okabe H, Masuda T, Mima K, Otao R, Chikamoto A, Doi K, Ishiko T, Takamori H, Yoshida M, Shiraishi S, Yamashita Y, Baba H. Liver functional volumetry for portal vein embolization using a newly developed 99mTc-galactosyl human serum albumin scintigraphy SPECT-computed tomography fusion system. *J Gastroenterol* 2011; **46**: 938-943 [PMID: 21523415 DOI: 10.1007/s00535-011-0406-x]

15 **Nanashima A**, Tobinaga S, Abo T, Sumida Y, Araki M, Hayashi H, Sakamoto I, Kudo T, Takeshita H, Hidaka S, Sawai T, Hatano K, Nagayasu T. Relationship of hepatic functional parameters with changes of functional liver volume using technetium-99m galactosyl serum albumin scintigraphy in patients undergoing preoperative portal vein embolization: a follow-up report. *J Surg Res* 2010; **164**: e235-e242 [PMID: 20869076 DOI: 10.1016/j.jss.2010.06.003]

16 **Ha-Kawa SK**, Tanaka Y, Hasebe S, Kuniyasu Y, Koizumi K, Ishii Y, Yamamoto K, Kashiwagi T, Ito A, Kudo M, Ikekubo K, Tsuda T, Murase K. Compartmental analysis of asialoglycoprotein receptor scintigraphy for quantitative measurement of liver function: a multicentre study. *Eur J Nucl Med* 1997; **24**: 130-137 [PMID: 9021109 DOI: 10.1007/BF02439544]

17 **Akaki S**, Okumura Y, Sasai N, Sato S, Tsunoda M, Kuroda M, Kanazawa S, Hiraki Y. Hepatectomy simulation discrepancy between radionuclide receptor imaging and CT volumetry: influence of decreased unilateral portal venous flow. *Ann Nucl Med* 2003; **17**: 23-29 [PMID: 12691127 DOI: 10.1007/BF02988255]

18 **Tsuruga Y**, Kamiyama T, Kamachi H, Shimada S, Wakayama K, Orimo T, Kakisaka T, Yokoo H, Taketomi A. Significance of functional hepatic resection rate calculated using 3D CT/(99m)Tc-galactosyl human serum albumin single-photon emission computed tomography fusion imaging. *World J Gastroenterol* 2016; **22**: 4373-4379 [PMID: 27158206 DOI: 10.3748/wjg.v22.i17.4373]

19 **Kamiyama T**, Nakanishi K, Yokoo H, Kamachi H, Tahara M, Yamashita K, Taniguchi M, Shimamura T, Matsushita M, Todo S. Perioperative management of hepatic resection toward zero mortality and morbidity: analysis of 793 consecutive cases in a single institution. *J Am Coll Surg* 2010; **211**: 443-449 [PMID: 20822741 DOI: 10.1016/j.jamcollsurg.2010.06.005]

20 **Sakuhara Y**, Abo D, Hasegawa Y, Shimizu T, Kamiyama T, Hirano S, Fukumori D, Kawamura T, Ito YM, Tha KK, Shirato H, Terae S. Preoperative percutaneous transhepatic portal vein embolization with ethanol injection. *AJR Am J Roentgenol* 2012; **198**: 914-922 [PMID: 22451561 DOI: 10.2214/AJR.11.6515]

21 **Ohshima S**. Volume analyzer SYNAPSE VINCENT for liver analysis. *J Hepatobiliary Pancreat Sci* 2014; **21**: 235-238 [PMID: 24520049 DOI: 10.1002/jhbp.81]

22 **Kanda Y**. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. *Bone Marrow Transplant* 2013; **48**: 452-458 [PMID: 23208313 DOI: 10.1038/bmt.2012.244]

23 **Isfordink CJ**, Samim M, Braat MNGJA, Almalki AM, Hagendoorn J, Borel Rinkes IHM, Molenaar IQ. Portal vein ligation versus portal vein embolization for induction of hypertrophy of the future liver remnant: A systematic review and meta-analysis. *Surg Oncol* 2017; **26**: 257-267 [PMID: 28807245 DOI: 10.1016/j.suronc.2017.05.001]

24 **Tashiro S**. Mechanism of liver regeneration after liver resection and portal vein embolization (ligation) is different? *J Hepatobiliary Pancreat Surg* 2009; **16**: 292-299 [PMID: 19333540 DOI: 10.1007/s00534-009-0058-x]

25 **Tsai CY**, Nojiri M, Yokoyama Y, Ebata T, Mizuno T, Nagino M. Uneven acute non-alcoholic fatty change of the liver after percutaneous transhepatic portal vein embolization in a patient with hilar cholangiocarcinoma - a case report. *BMC Gastroenterol* 2017; **17**: 144 [PMID: 29207941 DOI: 10.1186/s12876-017-0715-5]

26 **Miyake H**, Fujii M, Sasaki K, Ando T, Ikeyama S, Iwata T, Rokutan K, Tashiro S. Heat shock protein 70 induction in hepatocytes after right portal vein embolization. *Hepatogastroenterology* 2003; **50**: 2084-2087 [PMID: 14696469]

27 **Archer AE**, Rogers RS, Von Schulze AT, Wheatley JL, Morris EM, McCoin CS, Thyfault JP, Geiger PC. Heat shock protein 72 regulates hepatic lipid accumulation. *Am J Physiol Regul Integr Comp Physiol* 2018; **315**: R696-R707 [PMID: 29924632 DOI: 10.1152/ajpregu.00073.2018]

28 **Barth BK**, Fischer MA, Kambakamba P, Lesurtel M, Reiner CS. Liver-fat and liver-function indices derived from Gd-EOB-DTPA-enhanced liver MRI for prediction of future liver remnant growth after portal vein occlusion. *Eur J Radiol* 2016; **85**: 843-849 [PMID: 26971433 DOI: 10.1016/j.ejrad.2016.02.008]

29 **Hsiao IT**, Lin KJ, Chang SI, Yen TC, Chen TC, Yeh TS. Impaired liver regeneration of steatotic rats after portal vein ligation: a particular emphasis on (99m)Tc-DISIDA scintigraphy and adiponectin signaling. *J Hepatol* 2010; **52**: 540-549 [PMID: 20206399 DOI: 10.1016/j.jhep.2010.01.005]

30 **Schnitzbauer AA**, Lang SA, Goessmann H, Nadalin S, Baumgart J, Farkas SA, Fichtner-Feigl S, Lorf T, Goralcyk A, Hörbelt R, Kroemer A, Loss M, Rümmele P, Scherer MN, Padberg W, Königsrainer A, Lang H, Obed A, Schlitt HJ. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. *Ann Surg* 2012; **255**: 405-414 [PMID: 22330038 DOI: 10.1097/SLA.0b013e31824856f5]

31 **Schadde E**, Raptis DA, Schnitzbauer AA, Ardiles V, Tschuor C, Lesurtel M, Abdalla EK, Hernandez-Alejandro R, Jovine E, Machado M, Malago M, Robles-Campos R, Petrowsky H, Santibanes ED, Clavien PA. Prediction of Mortality After ALPPS Stage-1: An Analysis of 320 Patients From the International ALPPS Registry. *Ann Surg* 2015; **262**: 780-5; discussion 785-6 [PMID: 26583666 DOI: 10.1097/SLA.0000000000001450]

32 **Olthof PB**, Tomassini F, Huespe PE, Truant S, Pruvot FR, Troisi RI, Castro C, Schadde E, Axelsson R, Sparrelid E, Bennink RJ, Adam R, van Gulik TM, de Santibanes E. Hepatobiliary scintigraphy to evaluate liver function in associating liver partition and portal vein ligation for staged hepatectomy: Liver volume overestimates liver function. *Surgery* 2017; **162**: 775-783 [PMID: 28732555 DOI: 10.1016/j.surg.2017.05.022]

**Footnotes**

**Institutional review board statement:** This retrospective study was approved by the Institutional Review Board of Hokkaido University Hospital for Clinical Research on November 29, 2018 (Approval No. 018-0263).

**Informed consent statement:** This study was reviewed and approved by the Institutional Review Board of Hokkaido University Hospital for Clinical Research (Approval No. 018-0263), which waived the need for written informed consent due to the retrospective design.

**Conflict-of-interest statement:** The authors declare no conflicts of interest associated with this manuscript.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** November 16, 2020

**First decision:** December 20, 2020

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Japan

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Li HL **S-Editor:** Gao CC **L-Editor: P-Editor:**

**Figure Legends**







**Figure 1 Change in the volume of the future liver remnant after portal vein embolization.** A: Change in the volume of the future liver remnant (FLR) after portal vein embolization in the whole case. FLR volume (FLRV) (dashed line) and functional FLRV (solid line); B: Change in the volume of the FLR after portal vein embolization in the group with preoperative biliary drainage; C: Change in the volume of the FLR after portal vein embolization in the group without preoperative biliary drainage. a*P* < 0.01. W: Week.



**Figure 2 Change in the difference between the** **future liver remnant volume and the functional future liver remnant volume after** **portal vein embolization.** In three patients (solid lines), the functional future liver remnant volume became lower than the future liver remnant volume at 2 wk after portal vein embolization. W: Week.



**Figure 3 Change in the difference between the future liver remnant volume and the functional future liver remnant volume after portal vein embolization and biopsy findings in patient 1.** A:Change in future liver remnant volume (FLRV), functional FLRV (FFLRV), and future liver remnant (FLR) to spleen computed tomography (CT) attenuation ratio in patient 1. The FFLRV level remained below that of the FLRV at 2 wk after portal vein embolization (PVE). The decrease in the FLR to spleen CT attenuation ratio represents fatty changes in FLR at 5 wk after PVE; B: Biopsy findings in the FLR at 4 wk after PVE. The macro and micro-vesicular steatosis was more than 40%; C: At 13 wk after PVE, the steatosis had improved to approximately 10%. W: Week.

**Table 1 Patient characteristics at baseline (*n* = 33)**

|  |  |
| --- | --- |
| **Characteristics** | ***n*** |
| Age (yr), mean (range) | 67.7 (40-80) |
| Men/women | 20/13 |
| HBsAg positivity, *n* (%) | 3 (9.0) |
| HCV positivity, *n* (%) | 2 (6.1) |
| Diagnosis, *n* (%) |  |
| Hilar cholangiocarcinoma | 20 (60.6) |
| Hepatoma | 6 (18.2) |
| Gallbladder cancer | 3 (9.1) |
| Intrahepatic cholangiocarcinoma | 2 (6.1) |
| Metastatic tumor | 2 (6.1) |
| Child-Pugh score (5/6/7/8), *n* | 23/7/1/2 |
| Child-Pugh classification (A/B), *n* | 30/3 |
| ICGR15 (%), mean (range) | 10.1 (1.5-33.2) |
| Preoperative biliary drainage, *n* (%) | 17 (51.5) |
| Initial resection ratio (%), mean ± SD | 64.5 ± 5.48  |
| Initial CT volume of FLR (mL), mean ± SD | 410.9 ± 79.4 |
| Average time between PVE and operation, d (range) | 30.0 (15-94) |
| Type of hepatectomy, *n* (%) |  |
| Right hepatectomy+ caudal lobectomy | 19 (57.6) |
| Right hepatectomy | 9 (27.3) |
| Left trisectionectomy+ caudal lobectomy | 4 (12.1) |
| Left hepatectomy+ caudal lobectomy | 1 (3.0) |
| Biliary reconstruction, *n* (%) | 24 (72.7) |

HBsAg: Hepatitis B virus surface antigen; HCV: Hepatitis C virus; ICGR15: Indocyanine green retention at 15 min; SD: Standard deviation; CT: Computed tomography; FLR: Future liver remnant; PVE: Portal vein embolization.

**Table 2 Comparison of the initial liver function, future liver remnant volume, and functional future liver remnant volume between the groups with and without preoperative biliary drainage**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Group with preoperative biliary drainage (*n* = 17)** | **Group without preoperative biliary drainage (*n* = 16)** | ***P* value** |
| ICGR15 (%), mean ± SD | 9.09 ± 5.0 | 11.2 ± 7.2 | 0.28 |
| Initial resection ratio (%), mean ± SD | 64.6 ± 6.36 | 64.4 ± 4.57 | 0.692 |
| Initial FLRV (mL), mean ± SD | 403.8 ± 88.6 | 418.4 ± 70.3 | 0.402 |
| Initial FFLRV (mL), mean ± SD | 366.4 ± 118.7 | 384.0 ± 92.7 | 0.601 |
| FLRV at 1 wk (mL), mean ± SD | 515.7 ± 100.9 | 515.0 ± 101.1 | 0.914 |
| FFLRV at 1 wk (mL), mean ± SD | 592 ± 114.0 | 583.0 ± 101.0 | 0.986 |
| FLRV at 2 wk (mL), mean ± SD | 550.1 ± 86.6 | 561.1 ± 114.5 | 0.958 |
| FFLRV at 2 wk (mL), mean ± SD | 640.0 ± 105.8 | 613.0 ± 96.6 | 0.382 |

ICGR15: Indocyanine green retention at 15 min; SD: Standard deviation; FLRV: Future liver remnant volume; FFLRV: Functional future liver remnant volume.

**Table 3 Comparison of the background factors between the functional future liver remnant volume superior group and future liver remnant volume superior group**

|  |  |  |
| --- | --- | --- |
|  | **FFLRV superior group (*n* = 30)** | **FLRV superior group (*n* = 3)** |
| Age (yr), mean ± SD | 67.4 ± 9.1 | 69.7 ± 9.5 |
| Gender |  |  |
| Male, *n* (%) | 18 (60.0) | 2 (66.7) |
| Female, *n* (%) | 12 (40.0) | 1 (33.3) |
| Body mass index (kg/m2), mean ± SD | 21.8 ± 3.5 | 23.4 ± 7.0 |
| Comorbidity (*n*) | Diabetes (5), hypertension (3), dyslipidemia (1), COPD (1), alcoholism (1), angina (1), lacunar infarction (1) | Diabetes (1), fatty liver (1), alcoholism (1) |
| HBV/HCV infection (*n*) | 3/1 | 0/1 |
| Child-Pugh score, mean ± SD | 5.4 ± 0.9 | 5.7 ± 0.6 |
| ICGR15 (%), mean ± SD  | 10.4 ± 6.3 | 7.2 ± 2.0 |
| Initial resection ratio (%), mean ± SD | 64.3 ± 5.6 | 66.8 ± 4.4 |
| Initial FLRV (mL), mean ± SD | 405.4 ± 79.0 | 466.3 ± 73.2 |

Functional future liver remnant volume (FFLRV) superior group included the patients without FFLRV decrease below the future liver remnant volume (FLRV) at 2 wk after PVE. FLRV superior group included the patients with FFLRV decrease below the FLRV at 2 weeks after PVE. SD: Standard deviation; COPD: Chronic obstructive pulmonary disease; HBV: Hepatitis B virus; HCV: Hepatitis C virus; ICGR15: Indocyanine green retention at 15 min; FLRV: Future liver remnant volume; FFLRV: Functional future liver remnant volume.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**